Illinois Municipal Retirement Fund Takes Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Illinois Municipal Retirement Fund acquired a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 127,160 shares of the biotechnology company’s stock, valued at approximately $2,181,000. Illinois Municipal Retirement Fund owned 0.05% of ADMA Biologics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in shares of ADMA Biologics by 13.9% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company’s stock valued at $13,171,000 after purchasing an additional 80,400 shares during the period. Lord Abbett & CO. LLC acquired a new position in shares of ADMA Biologics in the third quarter valued at about $61,858,000. EWG Elevate Inc. acquired a new position in shares of ADMA Biologics in the fourth quarter valued at about $480,000. Citigroup Inc. increased its holdings in shares of ADMA Biologics by 251.7% in the third quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company’s stock valued at $7,741,000 after purchasing an additional 277,138 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of ADMA Biologics by 1,144.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock valued at $51,016,000 after purchasing an additional 2,613,482 shares during the period. 75.68% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ADMA has been the topic of a number of recent research reports. HC Wainwright upped their target price on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Raymond James upped their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th.

ADMA Biologics Stock Up 6.2 %

Shares of ADMA opened at $16.39 on Friday. The company has a market capitalization of $3.87 billion, a price-to-earnings ratio of 58.54 and a beta of 0.75. The stock’s 50-day moving average price is $16.75 and its 200-day moving average price is $17.98. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 52 week low of $5.08 and a 52 week high of $23.64.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.